Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has amended its loan and security agreement with Hercules Capital, Inc. Under the revised terms, Savara will gain access to up to an additional $75 million in debt funding upon FDA approval of its investigational therapy MOLBREEVI for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). This amendment strengthens Savara’s balance sheet and liquidity as it prepares for a potential product launch. The agreement maintains the original maturity date and interest-only period, and does not include any warrants. Combined with a previously announced $75 million royalty funding agreement with RTW, Savara expects to have approximately $150 million in non-dilutive capital available to support MOLBREEVI’s launch activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260127749473) on January 27, 2026, and is solely responsible for the information contained therein.